Access to integrated, community-based cancer treatment in jeopardy

In July 2013, the Medicare Patient Access to Cancer Treatment Act (H.R. 2869), a bipartisan bill, was introduced to remedy a flawed Medicare payment policy that pays more to hospitals than cancer care centers for the same care. This legislation would equalize reimbursements for cancer treatments regardless of whether a service is delivered in the hospital or a physician office. We encourage you to reach out to your Representatives and encourage them to cosponsor the Medicare Patient Access to Cancer Treatment Act.

Read more.

By WVCI


View all posts by WVCI
Posted January 21, 2014

Dr. Sharman published in the New England Journal of Medicine

Dr. Jeff Sharman, a hematologist oncologist at Willamette Valley Cancer Institute and Research Center, was published in the New England Journal of Medicine last week for clinical trials held at WVCI on a breakthrough drug for chronic lymphocytic leukemia (CLL).

Read more.

By WVCI


View all posts by WVCI
Posted June 26, 2013

OSMO appoints Dr. Ben Cho its president-elect

Dr. Ben Cho, medical oncology director at WVCI, was voted president-elect by the Oregon Society of Medical Oncology (OSMO) at its May 18th meeting in Ashland. As president-elect, Dr. Cho is slated to assume the presidency in May 2015.

Read more.

By WVCI


View all posts by WVCI
Posted May 28, 2013

Dr. Wendland featured in national journal

"This study was attractive because the drug was oral, and patients don't have to come into the center. They can take it from home," Dr. Wendland says.

Read more.

BY WVCI


View all posts by WVCI
Posted May 21, 2013

Clinical trials at WVCI supports FDA approval of new drug

The first two chronic lymphocytic leukemia (CLL) patients ever in the world to receive a new, potentially life-saving drug for B-cell cancers were part of a clinical trial run by Dr. Jeff Sharman at WVCI.

Read more.

By WVCI


View all posts by WVCI
Posted May 16, 2013